IPCA Laboratories Ltd
NSE:IPCALAB

Watchlist Manager
IPCA Laboratories Ltd Logo
IPCA Laboratories Ltd
NSE:IPCALAB
Watchlist
Price: 1 591.35 INR 1.13% Market Closed
Market Cap: 403.7B INR
Have any thoughts about
IPCA Laboratories Ltd?
Write Note

IPCA Laboratories Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IPCA Laboratories Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
IPCA Laboratories Ltd
NSE:IPCALAB
Note Receivable
â‚ą1.2B
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Note Receivable
â‚ą3.7B
CAGR 3-Years
9%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Note Receivable
â‚ą3.3B
CAGR 3-Years
1 392%
CAGR 5-Years
45%
CAGR 10-Years
0%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Note Receivable
â‚ą10.9B
CAGR 3-Years
-35%
CAGR 5-Years
-18%
CAGR 10-Years
-2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Note Receivable
â‚ą2.3B
CAGR 3-Years
87%
CAGR 5-Years
18%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Note Receivable
â‚ą1.5B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

IPCA Laboratories Ltd
Glance View

Market Cap
403.7B INR
Industry
Pharmaceuticals

Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,155 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 17 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., USA Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.

IPCALAB Intrinsic Value
1 210.96 INR
Overvaluation 24%
Intrinsic Value
Price

See Also

What is IPCA Laboratories Ltd's Note Receivable?
Note Receivable
1.2B INR

Based on the financial report for Jun 30, 2024, IPCA Laboratories Ltd's Note Receivable amounts to 1.2B INR.

What is IPCA Laboratories Ltd's Note Receivable growth rate?
Note Receivable CAGR 3Y
14%

Over the last year, the Note Receivable growth was 4%. The average annual Note Receivable growth rates for IPCA Laboratories Ltd have been 14% over the past three years .

Back to Top